Interleukins 1α and 1β secreted by some melanoma cell lines strongly reduce expression of MITF‐M and melanocyte differentiation antigens
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We report that melanoma cell lines expressing the interleukin‐1 receptor exhibit 4‐ to 10‐fold lower levels of mRNA of microphthalmia‐associated transcription factor (MITF‐M) when treated with interleukin‐1β. This effect is NF‐κB and JNK‐dependent. MITF‐M regulates the expression of melanocyte differentiation genes such as MLANA, tyrosinase and gp100, which encode antigens recognized on melanoma cells by autologous cytolytic T lymphocytes. Accordingly, treating some melanoma cells with IL‐1β reduced by 40–100% their ability to activate such antimelanoma cytolytic T lymphocytes. Finally, we observed large amounts of biologically active IL‐1α or IL‐1β secreted by two melanoma cell lines that did not express MITF‐M, suggesting an autocrine MITF‐M downregulation. We estimate that ∼13% of melanoma cell lines are MITF‐M‐negative and secrete IL‐1 cytokines. These results indicate that the repression of melanocyte‐differentiation genes by IL‐1 produced by stromal cells or by tumor cells themselves may represent an additional mechanism of melanoma immune escape.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · cited 1×
“Melanoma is a prime target of immunotherapy notably because spontaneous antitumoral T cell responses are frequent in melanoma patients.(1,2) Surprisingly, it was found that many of these T lymphocytes recognized differentiation antigens shared by normal melanocytes and melanoma cells.”
BackgroundUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“Expression of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase in metastatic melanoma tumor sites deprives surrounding T lymphocytes of tryptophan, thereby suppressing their function.(8) Melanoma cells themselves can alter the efficacy of antitumor responses.”
Background
Cited by
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma
Bald, T., Quast, T., Landsberg, J., Rogava, M., Glodde, N., Lopez-Ramos, D., Kohlmeyer, J., Riesenberg, S., van den Boorn-Konijnenberg, D., Hömig-Hölzel, C., et al. (2014) · Nature · doi:10.1038/nature13111 · Cited by 623
MITF in melanoma: mechanisms behind its expression and activity
Hartman, M. L., & Czyz, M. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1791-0 · Cited by 320
Khalili, J. S., Liu, S., Rodríguez-Cruz, T. G., Whittington, M., Wardell, S., Liu, C., Zhang, M., Cooper, Z. A., Frederick, D. T., Li, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1632 · Cited by 301
Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256
Boyajian, J. L., Ghebretatios, M., Schaly, S., Islam, P., & Prakash, S. (2021) · Nutrients · doi:10.3390/nu13124550 · Cited by 115
Ayuso, J. M., Sadangi, S., Lares, M., Rehman, S., Humayun, M., Denecke, K. M., Skala, M. C., Beebe, D. J., & Setaluri, V. (2021) · Lab on a Chip · doi:10.1039/d0lc00988a · Cited by 39
Metadata
- Authors
- Kholmanskikh, O., van Baren, N., Brasseur, F., Ottaviani, S., Vanacker, J., Arts, N., van der Bruggen, P., Coulie, P., & De Plaen, E.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2010-08-04
- Volume
- 127
- Issue
- 7
- Pages
- 1625-1636
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2069941983
- Cited by
- 70
- References
- 4
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.